Glycogen Storage Disease Drug Pipeline — PatSnap Eureka
Glycogen Storage Disease Drug Pipeline: ERT, mRNA & Gene Therapy Approaches
From approved enzyme replacement to next-generation mRNA, AAV gene therapy, and ASO substrate reduction — explore the full innovation landscape for Pompe disease and GSD Type III, mapped from patent filings and academic literature.
Two Primary Disease Contexts Driving GSD Pipeline Innovation
Pompe disease (GSD II) is caused by mutations in the GAA gene on chromosome 17, encoding lysosomal acid α-glucosidase (GAA), leading to progressive lysosomal glycogen accumulation principally in skeletal muscle, cardiac muscle, and the diaphragm. Over 560 mutations across the GAA gene have been reported, producing a clinical spectrum from fatal infantile-onset to attenuated late-onset phenotypes. Research published by the NIH highlights that GAA deficiency initiates a pathogenic cascade beyond lysosomal storage — including defective autophagy, impaired energy metabolism with glycolytic pathway downregulation, mitochondrial abnormalities, and dysregulated calcium homeostasis — all of which limit the efficacy of current ERT.
GSD Type III (GSDIII) is caused by mutations in the AGL gene, encoding glycogen debranching enzyme (GDE), resulting in accumulation of limit dextrin. The most prevalent subtype, GSDIIIa, involves liver, cardiac, and skeletal muscle; GSDIIIb is confined to liver. A 175-patient international cohort identifies non-missense AGL mutations as overrepresented, with 58 distinct mutations characterized across 76 families. Critically, GSD IIIa muscle biopsies exhibit vacuolar myopathy with autophagy impairment analogous to Pompe pathology — a mechanistic overlap that could enable knowledge transfer across programs. For further context on rare metabolic disease epidemiology, see data from Orphanet.
For GSD Type Ia, retrieved results identify the G6PC gene (encoding glucose-6-phosphatase, G6Pase) as the causal target, with mRNA therapy showing preclinical proof-of-concept. PatSnap's life sciences intelligence platform enables researchers to map these target-disease relationships across the full global patent and literature corpus.
Six Distinct Approaches Across the GSD Drug Pipeline
From approved ERT to preclinical gene therapy and commercially active mRNA patents, the GSD pipeline spans a broad spectrum of mechanistic strategies.
Enzyme Replacement Therapy (ERT)
Recombinant human GAA (alglucosidase alfa) is the only approved disease-specific therapy for Pompe disease, introduced clinically after 2006 based on work originating at Duke University. Clinical review data confirm efficacy in reversing cardiomyopathy and improving motor function in late-onset Pompe disease, but residual muscle weakness, hearing loss, arrhythmia risk, and autophagy failure persist. Next-generation rhGAA (AT-GAA; Amicus Therapeutics) can reverse extra-lysosomal pathogenic events including metabolic deficits and autophagic dysfunction in preclinical models. A moss-derived recombinant GAA variant with modified glycosylation patterns (paucimannosidic Man3 and high-mannose Man5 configurations) demonstrates differentiated uptake characteristics compared to M6P-receptor-dependent standard enzyme.
Duke University patent (AU) · Amicus AT-GAA (preclinical NIH data)mRNA Therapy
A 2025 European patent filing by Ultragenyx Pharmaceutical Inc. covers translatable polynucleotide and oligomer molecules designed to express human AGL protein or AGL-active fragments for GSD III — the most commercially advanced mRNA-based approach for GSD III in this dataset. For GSD Ia, Alexion Pharmaceuticals demonstrated that a single systemic injection of LNP-formulated human G6PC mRNA produced significant reductions in fasting hypoglycemia, hepatic glycogen, glucose-6-phosphate, and liver triglycerides for up to 7 days post-dose in a mouse model. The AGL gene's large coding sequence (~7 kb) has historically challenged AAV-based approaches; mRNA/translatable polynucleotide strategies may circumvent this packaging constraint.
Ultragenyx EP 2025 · Alexion G6PC preclinical dataGene Therapy (AAV & Lentiviral)
Gene therapy for Pompe disease has reached preclinical proof-of-concept across at least three distinct vector strategies. Sorbonne University demonstrated AAV-mediated hepatic expression of secretable engineered GAA (secGAA) achieved full phenotypic rescue in severely affected 9-month-old Gaa-knockout mice, with sustained benefit over 9 months post-treatment. Erasmus University Medical Center's lentiviral HSC gene therapy achieved near-normalization of glycogen in heart, muscles, and brain — uniquely addressing CNS involvement that ERT cannot reach due to the blood-brain barrier. For GSD III, dual AAV vector delivery of full-length AGL transgene achieved nearly complete rescue of muscle function in the murine model.
AAV-secGAA (Sorbonne) · HSC-GT (Erasmus) · Dual AAV-AGL (Tokyo)Antisense Oligonucleotides (ASOs)
Two distinct ASO strategies are represented: substrate reduction therapy via GYS1 suppression, where a Genzyme/Sanofi phosphorodiamidate morpholino oligonucleotide targeting Gys1 invokes exon skipping to reduce glycogen biosynthesis as an adjuvant to ERT in Pompe mice; and splicing correction for late-onset Pompe, where ICGEB (Trieste) developed antisense morpholino oligonucleotides to rescue normal exon 2 splicing in the presence of the common late-onset mutation c.-32-13T>G in intron 1. AMO treatment in patient myotubes resulted in glycogen reduction — a direct therapeutic effect in patient-derived cells.
Genzyme/Sanofi GYS1-PMO · ICGEB AMO splicing correctionPharmacological Chaperone Therapy
AT2220 (duvoglustat hydrochloride; 1-deoxynojirimycin), a small molecule pharmacological chaperone from Amicus Therapeutics, binds and stabilizes mutant GAA forms, particularly the ER-retained P545L mutant. AT2220 increased the specific activity of mutant GAA, improved lysosomal delivery, and promoted glycogen reduction in transgenic Pompe mice. Chaperone therapy targets protein misfolding upstream of lysosomal deficit and is framed in the literature as a co-administration strategy with ERT to enhance trafficking of therapeutic enzyme.
AT2220 / duvoglustat · Amicus Therapeutics · P545L mutant targetSmall Molecules & Genome Editing
Hebrew University identified 144DG11, a novel small molecule discovered by high-throughput screen, as a glycogen-reducing lead compound in Adult Polyglucosan Body Disease (APBD) — a GSD IV variant. 144DG11 prolonged survival and improved motor parameters in a Gbe knockin APBD mouse model, reducing polyglucosan bodies in brain, liver, heart, and peripheral nerve. Ramot at Tel-Aviv University Ltd. holds three active IL patents (2022–2023) on small molecule compounds for GSD treatment. CRISPR Therapeutics AG holds a pending IL patent covering both ex vivo and in vivo editing approaches to modulate G6PC expression and G6Pase activity for GSD Ia.
144DG11 (Hebrew Univ) · Ramot IL patents · CRISPR Therapeutics AGKey Molecular Targets & Assignee Activity
Evidence distribution across molecular targets and commercial assignees, derived from patent filings and academic literature in the PatSnap Eureka dataset.
Molecular Targets by Evidence Records
GAA is the most extensively characterized target in this dataset, with AGL emerging as the primary focus for GSD III therapeutics.
Innovation Activity: Commercial vs. Academic
Activity in this dataset is roughly balanced between patent-driven commercial IP and literature-driven academic research, with commercial patents concentrated in GSD III, genome editing, and small molecules.
Key Commercial & Academic Players in the GSD Pipeline
| Assignee / Institution | Modality Focus | Disease Target | IP Status |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | mRNA / Translatable polynucleotides | GSD III (AGL) | Active EP 2025 |
| Amicus Therapeutics Inc. | Pharmacological chaperone (AT2220); next-gen ERT (AT-GAA) | Pompe disease (GAA) | Academic paper |
| Ramot at Tel-Aviv University Ltd. | Small molecule compounds (Formulae I–IV) | GSD (broad) | 3 Active IL Patents 2022–23 |
| CRISPR Therapeutics AG | Genome editing (ex vivo & in vivo) | GSD Ia (G6PC) | Pending IL Patent |
| Duke University | ERT (historical); GSD III natural history | GSD II, GSD III | AU Patent (2007) |
| Genzyme / Sanofi | ERT; ASO substrate reduction (GYS1-PMO) | Pompe disease (GAA) | Academic papers |
Track GSD Patent Filings in Real Time
PatSnap Eureka alerts you when new assignees enter the GSD space or existing players file continuation claims.
Emerging Directions with Preclinical Validation
Retrieved results signal several combination and emerging strategies with biological validation in preclinical murine models.
ERT + Substrate Reduction (GYS1-ASO)
The Genzyme/Sanofi PMO study explicitly positions GYS1-targeting ASOs as an "adjuvant strategy" to ERT, recognizing that reducing glycogen synthesis load could synergize with improved lysosomal clearance. This combination rationale is biologically validated in preclinical murine models. PatSnap Analytics can map the white space in combination therapy IP.
ERT + Pharmacological Chaperone
AT2220 data from Amicus Therapeutics describe chaperone-mediated stabilization of mutant GAA improving both specific activity and lysosomal delivery — framed in the literature as a co-administration strategy with ERT to enhance trafficking of therapeutic enzyme. Dual-mechanism combination regimen patents may represent a differentiated IP opportunity not yet saturated in retrieved filings.
Secretable AAV-GAA: Liver as Bioreactor
The secGAA AAV approach from Sorbonne University signals an emerging direction in which the liver acts as a bioreactor for continuous systemic secretion of engineered GAA, bypassing the need for repeated infusions and achieving muscle correction via circulating enzyme — with full phenotypic rescue in severely affected 9-month-old Gaa-knockout mice.
AAV Gene Therapy + Autophagy Modulation
A NIH study demonstrated that PGC-1α-mediated fiber-type conversion (from fast glycolytic to slow oxidative fibers) activates lysosomal and autophagosomal biogenesis, potentially rendering therapy-resistant fast fibers amenable to ERT or AAV-delivered enzyme — a combination biology approach pairing metabolic reprogramming with enzyme replacement.
From Preclinical Models to Translational Evidence
Alglucosidase alfa (ERT, Pompe disease): Systematic review data confirm alglucosidase alfa is licensed for Pompe disease and has been used clinically since 2006, with documented outcomes in LOPD patients analyzed across EMBASE/MEDLINE publications through 2012. The review confirms clinical benefit in respiratory and motor outcomes, with residual disease burden acknowledged.
AT-GAA (next-generation ERT): A preclinical study from the NIH specifically references AT-GAA as a "recently developed replacement enzyme," demonstrating reversal of metabolic abnormalities and energy deficit in Pompe muscle in a preclinical setting. The study is framed as relevant to clinical translation but the data presented are pre-clinical.
Myobundle model (Duke University): In vitro treatment of infantile-onset Pompe disease myobundles with either rhGAA or AAV-mediated hGAA expression yields glycogen clearance but incomplete correction of contractile function — an IND-enabling characterization signal rather than clinical data.
iPSC-derived neural stem cell model (NIH): Patient-derived neural stem cells were used to model CNS involvement, evaluating recombinant rhGAA alongside hydroxypropyl-β-cyclodextrin and δ-tocopherol as potential therapeutic agents — all preclinical. No retrieved result contains explicit data from registered clinical trials, regulatory submissions, or approved clinical outcomes for gene therapy, mRNA, or ASO approaches in Pompe or GSD III. Researchers can access ClinicalTrials.gov for registered trial data. PatSnap customers use Eureka to bridge patent signals with clinical development timelines.
Glycogen Storage Disease Drug Pipeline — key questions answered
Pompe disease (GSD II) is caused by mutations in the GAA gene on chromosome 17, encoding lysosomal acid α-glucosidase, leading to progressive lysosomal glycogen accumulation in skeletal muscle, cardiac muscle, and the diaphragm. GAA deficiency initiates a pathogenic cascade beyond lysosomal storage, including defective autophagy, impaired energy metabolism with glycolytic pathway downregulation, mitochondrial abnormalities, and dysregulated calcium homeostasis — all of which limit the efficacy of current ERT.
GSD Type III (GSDIII) is caused by mutations in the AGL gene, which encodes amylo-alpha-1,6-glucosidase/4-alpha-glucanotransferase (glycogen debranching enzyme, GDE), resulting in accumulation of limit dextrin (abnormally branched glycogen). The most prevalent subtype, GSDIIIa, involves liver, cardiac, and skeletal muscle; GSDIIIb is confined to liver. GSD IIIa muscle biopsies exhibit vacuolar myopathy with autophagy impairment analogous to Pompe pathology.
Ultragenyx Pharmaceutical Inc. holds an active EP patent (filed/published 2025) covering translatable polynucleotide and oligomer molecules designed to express human AGL protein or AGL-active fragments for GSD III. This represents the most recent and commercially advanced mRNA-based approach for GSD III in the dataset.
Gene therapy for Pompe disease has reached preclinical proof-of-concept across at least three distinct vector strategies: AAV-secretable GAA (liver-targeted, from Sorbonne University, achieving full phenotypic rescue in severely affected 9-month-old Gaa-knockout mice), lentiviral hematopoietic stem cell gene therapy (Erasmus University Medical Center, achieving near-normalization of glycogen in heart, muscles, and brain), and AAV-hGAA. Each has distinct tissue tropism profiles and CNS access characteristics.
Two distinct ASO strategies are represented: substrate reduction therapy via Gys1 suppression, where a phosphorodiamidate morpholino oligonucleotide targeting Gys1 invokes exon skipping to reduce glycogen biosynthesis as an adjuvant to ERT in Pompe mice; and splicing correction in late-onset Pompe, where antisense morpholino oligonucleotides rescue normal exon 2 splicing in the presence of the common late-onset mutation c.-32-13T>G in intron 1, resulting in glycogen reduction in patient myotubes.
Retrieved results signal several combination strategies with preclinical validation: ERT plus substrate reduction (ASO/GYS1 suppression), where the Genzyme/Sanofi PMO study positions GYS1-targeting ASOs as an adjuvant to ERT; ERT plus pharmacological chaperone, where AT2220 from Amicus Therapeutics stabilizes mutant GAA improving lysosomal delivery; and AAV gene therapy plus autophagy modulation via PGC-1α-mediated fiber-type conversion to render therapy-resistant fast fibers amenable to ERT or AAV-delivered enzyme.
Still have questions about the GSD drug pipeline? Let PatSnap Eureka answer them for you.
Ask Eureka About GSD TherapeuticsAccelerate Your GSD Pipeline Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map rare disease patent landscapes, identify white space, and track competitor programs across ERT, mRNA, gene therapy, and beyond.
References
- Pompe disease: pathogenesis, molecular genetics and diagnosis — Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, 2020
- Pompe Disease: New Developments in an Old Lysosomal Storage Disorder — Cell and Developmental Biology Center, NHLBI, NIH, 2020
- Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease — Cell and Developmental Biology Center, NHLBI, NIH, 2020
- Pompe disease: from pathophysiology to therapy and back again — Laboratory of Muscle Stem Cells and Gene Regulation, NIAMS, NIH, 2014
- Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome — APHP, Hôpitaux Universitaires Paris Sud / Paris Sud University, 2016
- Deep morphological analysis of muscle biopsies from type III glycogenosis (GSDIII) — National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, 2019
- G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a — Alexion Pharmaceuticals, Inc., 2018
- Treatment of glycogen storage disease type II — Duke University, 2007, AU [Patent]
- Alglucosidase alfa: 5 years of experience in late-onset Pompe disease — Friedrich-Baur-Institute, Department of Neurology, University of Munich, 2013
- Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease — Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, 2020
- Therapeutics for glycogen storage disease type iii — Ultragenyx Pharmaceutical Inc., 2025, EP [Patent]
- Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase — Sorbonne Université, 2020
- Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease — Center for Lysosomal and Metabolic Diseases, Erasmus University Medical Center, 2020
- Gene Therapy of Glycogenosis Type 2 Using SIN-Lentiviral Vectors — Institut Cochin, INSERM U567, 2006
- Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease — Genzyme, A Sanofi Company, 2014
- Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology — ICGEB, Trieste, 2017
- The Pharmacological Chaperone AT2220 Increases the Specific Activity and Lysosomal Delivery of Mutant Acid Alpha-Glucosidase, and Promotes Glycogen Reduction in a Transgenic Mouse Model of Pompe Disease — Amicus Therapeutics Inc., 2014
- A new drug candidate for glycogen storage disorders enhances glycogen catabolism: Lessons from Adult Polyglucosan Body Disease models — Hadassah–Hebrew University Medical Center, 2021
- Compounds for the treatment of glycogen storage disorders — Ramot at Tel-Aviv University Ltd., 2022, IL [Patent]
- Compounds for the treatment of glycogen storage disorders — Ramot at Tel-Aviv University Ltd., 2023, IL [Patent]
- Compounds for the treatment of glycogen storage disorders — Ramot at Tel-Aviv University Ltd., 2022, IL [Patent]
- Materials and methods for treatment of glycogen storage disease type 1a — CRISPR Therapeutics AG, 2018, IL [Patent]
- National Institutes of Health (NIH) — Referenced for NIH NHLBI and NIAMS research programs on Pompe disease pathophysiology and therapeutic development
- Orphanet — Rare Disease Database — Reference resource for glycogen storage disease epidemiology and classification
- ClinicalTrials.gov — Registry for registered clinical trials in GSD, Pompe disease, and related rare metabolic disorders
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.